Hims & Hers (HIMS) shares rise 8% amid FDA review of peptides
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowShares of Hims & Hers Health (HIMS) increased by over 8% to approximately $26 following the FDA's announcement to initiate a formal review of wellness peptides. The review includes potential inclusion of multiple peptide-related substances on the 503A bulks list. Bank of America raised its price target for HIMS from $21 to $25 while maintaining a 'Neutral' rating. While the review process introduces strategic optionality for HIMS, the immediate impact on earnings remains uncertain, contingent upon future FDA decisions.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Bank of America Corporation (BAC)
Bank of America is one of the largest U.S. banks, offering consumer banking, wealth management, and investment banking.
The Financials sector covers banks, insurers and capital-markets firms at the center of the economy.
Earlier BAC news
- Bank of America (BAC) 30% Jump in Equities Revenue Drives Earnings Beat
- Stocks Making Moves Premarket: Bank of America, Morgan Stanley
- Bank of America (BAC) Reports 17% Profit Increase, Tops Estimates
- Bank of America (BAC) Q1 Earnings Beat Estimates with $30.43B Revenue
- Bank of America (BAC) Anticipated to Produce Solid Results
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
